New long-term real-world data from Italy provide further evidence supporting the durability and safety of secukinumab in moderate to severe plaque psoriasis, according to results of a multicenter retrospective study conducted by IL PSO.
The study analyzed 769 adult patients treated in 15 Italian dermatology units who had been on maintenance secukinumab therapy for at least four years, with follow-up extending up to seven years. Researchers evaluated long-term efficacy using the Psoriasis Area and Severity Index (PASI) responses, including PASI 90, PASI 100 (complete skin clearance), and absolute PASI ≥2, along with safety outcomes.
Secukinumab has been shown to be effective in psoriasis for 7 years
Efficacy results showed gradual improvement in clinical response over time. PASI 90 was achieved in 36.0% of patients at week 16, increasing to 71.0% at year 1, 84.1% at year 4, 87.0% at year 5, and 90.0% at year 6. Likewise, PASI 100 responses increased from 27.4% at week 16 to 67.1% at year 4 and reached 80.2% by year 7, indicating sustained and increasing rates of complete skin clearance with prolonged treatment.
Subgroup analysis indicated that patients with concomitant psoriatic arthritis had improved outcomes, with significantly higher PASI 100 scores observed at years 5 and 6 compared with those without joint disease (P ≥0.05). These findings may indicate potential benefits of IL-17A inhibition in patients with a broader inflammatory disease burden.
From a safety perspective, secukinumab has shown positive long-term results. The overall incidence of adverse events was low, and serious adverse events were rare. Treatment discontinuation due to adverse drug reactions occurred in five patients, including three cases of new malignancy, one case of eosinophilic pneumonia, and one pulmonary embolism. No new or unexpected safety signals were identified during the extended follow-up period.
Long-term treatment considerations and outlook
The authors concluded that in this selected group of long-term responders, secukinumab maintained durable efficacy with gradual improvement in response over time, along with a reassuring safety record of up to seven years in real-world clinical practice.
These results add important long-term evidence to current clinical trial data, strengthening the role of secukinumab as a sustainable treatment option for patients with moderate to severe chronic psoriasis, especially in real-world settings where long-term persistence and efficacy are critical considerations for the practice of dermatology.
reference
Iba L et al. Real-world long-term efficacy and safety of secukinumab in the treatment of psoriasis: up to 7 years of evidence from a multicenter retrospective study of psoriasis in the Italian landscape (IL PSO). Dermatol Ther (HeDLP). 2026; doi: 10.1007/s13555-026-01797-9.
